Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$9056.4.

  • Ascendis Pharma A's EPS (Basic) fell 5372.94% to -$9056.4 in Q4 2025 from the same period last year, while for Dec 2025 it was -$9056.4, marking a year-over-year decrease of 5372.94%. This contributed to the annual value of -$4.25 for FY2025, which is 3910.54% up from last year.
  • As of Q4 2025, Ascendis Pharma A's EPS (Basic) stood at -$9056.4, which was down 5372.94% from -$19429.5 recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's EPS (Basic) registered a high of $56971.7 during Q1 2024, and its lowest value of -$59937.3 during Q1 2025.
  • Over the past 5 years, Ascendis Pharma A's median EPS (Basic) value was -$7473.8 (recorded in 2025), while the average stood at -$7118.6.
  • In the last 5 years, Ascendis Pharma A's EPS (Basic) plummeted by 27932427.57% in 2023 and then skyrocketed by 20098.75% in 2024.
  • Quarter analysis of 5 years shows Ascendis Pharma A's EPS (Basic) stood at -$1.94 in 2021, then tumbled by 91.03% to -$3.7 in 2022, then crashed by 279324.28% to -$10336.4 in 2023, then skyrocketed by 43.01% to -$5891.1 in 2024, then crashed by 53.73% to -$9056.4 in 2025.
  • Its EPS (Basic) was -$9056.4 in Q4 2025, compared to -$19429.5 in Q3 2025 and $18132.4 in Q2 2025.